Advanced Search


Study ID Status Title Patient Level Data
108890 Completed A Phase I, open-label, vaccination study to evaluate the safety and immunogenicity of the GSK Biologicals recombinant CMV gB sub-unit vaccine GSK1492903A in CMV-seronegative healthy male adult subjects
108919 Relinquished A Randomized, Open-Label, Phase III Study of Taxane Based Chemotherapy with Lapatinib or Trastuzumab as First-Line Therapy for Women with HER2/neu Positive Metastatic Breast Cancer
108933 Completed Phase IIIb, Observer-blind Study to Compare Immunogenicity of GSK Biologicals' HPV-16/18 L1/AS04 Vaccine Versus Gardasil® [Quadrivalent Human Papillomavirus (HPV-6,11,16,18 L1 VLP) Recombinant Vaccine Merck & Co., Inc.] Study Listed on
108984 Completed To Evaluate Immune Response to a Hepatitis B Vaccine (Engerix™-B ) Challenge Dose in Healthy Subjects Who Received GSK Biologicals' Hepatitis B Vaccine (Engerix™-B ) Approximately 20 Years Ago as Primary Vaccination at 0, 1, 2 and 12 Months. Study Listed on
108988 Completed Administration of a challenge dose of hepatitis B vaccine in subjects who previously received Engerix™-B vaccine. Study Listed on
109035 Completed A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating the Efficacy and Safety of GSK163090 in Subjects with Major Depressive Disorder Study Listed on
109059 Completed A Phase II Study to Evaluate: Delay in Intravaginal Ejaculatory Latency Time (IELT), Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Two Oral Doses of GSK557296 in a Randomized, Double Blind, Placebo-Controlled, Parallel Group Study in Men with Premature Ejaculation Study Listed on
109063 Relinquished Non-inferiority of GSK Biologicals’ meningococcal vaccine 134612 given concomitantly with GSK Biologicals’ Twinrix™ versus 134612 alone and Twinrix™ alone in healthy subjects aged 11 through 17 years. Study Listed on
109067 Relinquished Lot-to-Lot Consistency, Non-Inferiority Versus Mencevax™ and Evaluation of the co-Administration With Fluarix™ of GSK Biologicals' Meningococcal Vaccine GSK134612, in Healthy Subjects Aged 18 Through 55 Years of Age Study Listed on
109069 Completed Primary vaccination study in subjects aged 11-17 years to demonstrate the non-inferiority of GSK Biologicals' Meningococcal vaccine GSK134612 vaccine versus Mencevax™ ACWY Study Listed on
109117 Completed Human Papillomavirus (HPV) Type Distribution in Adult African Women Diagnosed With Invasive Cervical Cancer
109179 Completed Immunogenicity and safety study of GlaxoSmithKline Biologicals' HPV vaccine GSK580299 administered according to an alternative dosing schedule as compared to the standard dosing schedule in young female subjects aged 15-25 years Study Listed on
109216 Completed Immunogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) liquid vaccine (GSK 357941A) in healthy infants. Study Listed on
109275 Completed An Open-Label, Two-Part, Single Sequence Study to Examine the Effects of Esomeprazole on the Pharmacokinetics of Orally Administered Lapatinib in Subjects with Metastatic ErbB2
109315 Completed A Retrospective Study of Healthcare Utilization and Costs of Step-Down Therapy in Asthma Patients Receiving Fluticasone Propionate/Salmeterol Combination
109350 Completed A Multicentre, Randomized, Open-label Study to Evaluate the Efficacy andSafety of Fondaparinux versus Low Molecular Weight Heparin(Nadroparin) in Patients Requiring Rigid or Semi-rigid Immobilization for at least 21 Days and up to 45 Days because of Isolated Non-surgical Below-Knee Injury
109355 Completed To estimate the burden of rotavirus gastroenteritis (RV GE) in children less than 5 years of age in Greece
109375 Relinquished Study to assess immunogenicity, reactogenicity and safety of primary vaccination with GSK Biologicals' MenACWY vaccine (GSK134612) given as 1 or 2 doses to healthy toddlers 9-12 months of age Study Listed on
109377 Relinquished Study to Assess Immunogenicity, Reactogenicity and Safety of 1 Dose of GSK Biologicals' Meningococcal Vaccine GSK134612 vs. 1 Dose of Sanofi-Pasteur's Menactra® in Healthy Subjects 10-25 Years. Study Listed on
109385 Completed A randomized, open label, 4 period crossover study in healthy subjects to determine the effect of particle size on the pharmacokinetics of a single mg dose of GW856553
109393 Completed An open-label, multi-centre, randomized study to investigate patient preference on dosing in the once-monthly ibandronate and the once-weekly risedronate in Korean women with postmenopausal osteoporosis. A six-month, two-sequence, and two period crossover study
109477 Completed Prospective epidemiological study of the prevalence of HLAB*5701 in HIV-1 infected patients
109493 Terminated GSK1572932A Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with resectable MAGE-A3 positive Non-Small Cell Lung Cancer Study Listed on
109495 Completed Non-inferiority of GSK Biologicals' Meningococcal vaccine GSK134612 versus Mencevax™ in healthy subjects aged 2 through 10 years of age Study Listed on
109507 Completed Booster Vaccination With Pneumococcal Vaccine GSK1024850A, a DTPa-Combined and MenC or Hib-MenC Vaccines Study Listed on



For more information on this register please email

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party. is a database that provides summary protocol information for ongoing clinical trials. is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.